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Abstract
Mutations in LRRK2 (leucine-rich repeat kinase 2) have been identified as major genetic determinants of Parkinson’s disease
(PD). The most prevalent mutation, G2019S, increases LRRK2’s kinase activity, therefore understanding the sites and
substrates that LRRK2 phosphorylates is critical to understanding its role in disease aetiology. Since the physiological
substrates of this kinase are unknown, we set out to reveal potential targets of LRRK2 G2019S by identifying its favored
phosphorylation motif. A non-biased screen of an oriented peptide library elucidated F/Y-x-T-x-R/K as the core dependent
substrate sequence. Bioinformatic analysis of the consensus phosphorylation motif identified several novel candidate
substrates that potentially function in neuronal pathophysiology. Peptides corresponding to the most PD relevant proteins
were efficiently phosphorylated by LRRK2 in vitro. Interestingly, the phosphomotif was also identified within LRRK2 itself.
Autophosphorylation was detected by mass spectrometry and biochemical means at the only F-x-T-x-R site (Thr 1410)
within LRRK2. The relevance of this site was assessed by measuring effects of mutations on autophosphorylation, kinase
activity, GTP binding, GTP hydrolysis, and LRRK2 multimerization. These studies indicate that modification of Thr1410 subtly
regulates GTP hydrolysis by LRRK2, but with minimal effects on other parameters measured. Together the identification of
LRRK2’s phosphorylation consensus motif, and the functional consequences of its phosphorylation, provide insights into
downstream LRRK2-signaling pathways.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder that is
associated with progressive loss of dopaminergic neurons in the
substantia nigra. Demise of dopaminergic neurons leads to the
clinical features of PD which include bradykinesia, rigidity, and
resting tremor [1]. Though most PD cases are sporadic, there are
several genetic determinants such as mutations in SNCA, Parkin,
PINK1, DJ-1 and LRRK2 (reviewed in [2]). Linkage analysis studies
have shown that missense mutations in leucine-rich repeat kinase 2
(LRRK2) lead to an autosomal late-onset form of PD [3,4].
LRRK2 is a 286 kDa cytoplasmic protein with GTPase and kinase
domains as well as multiple protein-protein interaction domains.
Mutations have been identified throughout the protein with the
most common mutation, G2019S, residing in its kinase domain
[5,6]. In vitro data has suggested that the G2019S substitution
augments kinase activity by at least 2-fold [7–9], therefore making
the study of LRRK2’s kinase activity important for understanding
disease aetiology and for development of therapeutics.
PD is characterized pathologically by presence of Lewy bodies
composed of a-synuclein and degeneration primarily of dopami-
nergic neurons. Several cellular mechanisms underlie these
pathological features including mitochondrial dysfunction, protein
aggregation, oxidative stress, and synaptic dysregulation [10–14].
LRRK2 has been implicated in many of these pathophysiological
functions. Patients carrying LRRK2 mutations develop patholog-
ical inclusions composed of a-synuclein and ubiquitin aggregates
within dopaminergic neurons of the substantia nigra [4], and
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models [15]. Drosophila expressing mutant forms of LRRK2 have
higher levels of hydroxyl-free radicals than dLRRK2 null and
heterozygote flies suggesting a function for LRRK2 in oxidative
stress [16]. A fraction of LRRK2 co-localizes in synaptic vesicles
and overexpression of LRRK2 mutants impairs synaptic vesicle
endocytosis [17]. These studies suggest a role for LRRK2 in the
pathogenic pathways of PD, but the exact pathways linking the
kinase to these functions remain unknown. Fundamental to
addressing these questions is the identification of LRRK2’s
physiological substrate(s).
In this study, two oriented degenerate peptide library scans were
employed to identify a LRRK2 G2019S phosphorylation motif as
F/Y-x-T-x-R/K. This motif resides within a number of proteins
including LRRK2 itself at Thr1410. This Thr residue is found in
the ROC domain of LRRK2 and was demonstrated to be a site of
autophosphorylation by mass spectrometry. Potential functional
relevance of this phosphorylation was evidenced by the finding
that a T1410A mutation reduced GTPase activity but not GTP
binding, autophosphorylation, or kinase activity. The identifica-
tion of this motif and potential substrates suggests mechanisms by
which LRRK2 can function in PD relevant pathways.
Methods
Materials
Biotinylated peptide substrates were purchased from Anaspec,
Inc. Positional scanning peptide library was designed and
prepared as described by Turk et al. [18]. Peptide concentration
was calculated based on the molar absorptivity of the peptides at
280 nm. Recombinant GST-tagged LRRK2 protein 970-2527
(wildtype, G2019S, R1441C, T1410A (G2019S), and D1994A)
were obtained from Invitrogen. ATP and GTP were obtained
from Sigma. Full length WT-LRRK2 pCMV6-XL5 was pur-
chased from Origene (NM_198578.2). PCR was used to add a 59
KOZAK sequence, 59 HA tag, and 39 Myc tag. All point
mutations including G2019S, D1994N, K1347A, and T1410A
were inserted using Quickchange site-directed mutagenesis.
Antibodies utilized were rabbit phospho-threonine-x-arginine (Cell
Signaling Technology), GST-HRP (GE Healthcare), rat HA-HRP
(Roche Applied Science), mouse Flag M2-HRP (Sigma), and
mouse actin-HRP (Sigma). A rabbit polyclonal phospho-specific
antibody against LRRK2 Thr 1410 was produced by 21
st Century
Biochemicals using a KLH-coupled synthetic phosphopeptide
corresponding to residues surrounding Thr 1410 of human
LRRK2 (acetyl-THPHFM[pT]QRALYLAC-amide).
Cell culture, transfection, and immunoprecipitation
HEK-293FT cells (Invitrogen) were cultured in complete
Dulbecco’s Modified Eagle Medium and maintained at 37uCi n
5% CO2. Transient transfections were performed using FuGENE
HD (Roche Applied Science). For biochemical experiments HEK-
293FT cells were cultivated for 72 hours. Lysates were prepared
on ice with 20 mM Tris, pH 8.0, 135 mM NaCl, 1 mM MgCl2,
0.1 mM CaCl2, 10% glycerol, 1% NP-40, 50 mM b-glycerol
phosphate, 1 mg/mL leupeptin, 100 mg/mL phenylmethylsulfonyl
fluoride, 1 mM sodium fluoride, 1 mg/mL aprotinin, and
phosphatase inhibitor cocktails 1 and 2 (Sigma). Protein
concentrations in the resulting supernatants were quantitated
using standard BCA protein assay (Pierce). For immunoprecipi-
tations, 2.5 mg lysates were incubated with EZview Red Anti-HA
affinity gel (Sigma) overnight at 4uC. Precipitated immunocom-
plexes were washed in the lysis buffer and either assayed for
activity or subjected to immunoblot analysis by boiling samples in
LDS sample buffer with reducing agent (Invitrogen). Samples were
separated on 3–8% NuPAGE Tris-Acetate gels (Invitrogen),
transferred onto nitrocellulose membranes (Invitrogen), and
processed for western analysis with anti-pT1410 LRRK2 or
anti-HA antibodies.
Kinase assay with biotinylated peptide substrates
Kinase assays were performed with 5 nM recombinant LRRK2
G2019S or LRRK2 D1994A (Invitrogen), 200 mM biotinylated
peptide, 1 mCi of [c-
33P] ATP, and 200 mM ATP in a total volume
of 25 mL of kinase buffer (25 mM MOPS, pH 7.2, 12.5 mM b-
glycerophosphate, 25 mM MgCl2, 5 mM EGTA, 2 mM EDTA,
0.002% BSA, and 0.25 mM DTT). Kinase reactions were setup
such that LRRK2 protein and [
33P] ATP were pre-incubated at
30uC for 30 minutes followed by addition of the peptide substrate
for 30 additional minutes. In indicated experiments, HA-tagged
LRRK2 protein immunoprecipitated from HEK-293FT cells was
used. Protein concentration and incubation time were optimized
to obtain approximately 10% peptide phosphorylation. Reactions
were terminated by adding 12.5 mL 7.5 M guanidine hydrochlo-
ride and 5 mL of the reaction was spotted onto SAM
2 Biotin
Capture Membrane (Promega) [19]. All reactions were done in
triplicate. Washes were performed as described by Turk et al. and
the membrane squares were air dried for 1 hour [18]. Finally,
5 mL of Opti-Fluor (Perkin-Elmer) was added to each membrane
square and emissions were measured in a scintillation counter
(Beckman-Coulter).
Autophosphorylation assay
5 nM LRRK2 protein (wildtype, G2019S, or T1410A
(G2019S)) was incubated for 30 min at 30uC with 1 mCi of
[c-
33P] ATP and 200 mM ATP in kinase buffer as described
above. As controls, reactions were performed in the absence of
LRRK2 protein or ATP. Where indicated, HA-tagged LRRK2
protein immunoprecipitated from HEK-293FT cells was used.
Reactions were stopped by adding LDS sample buffer with
reducing agent (Invitrogen) followed by boiling. Samples were
separated on 7% NuPAGE Tris-Acetate gels (Invitrogen) and
transferred onto nitrocellulose membranes (Invitrogen). The
nitrocellulose membranes were probed with anti-pT1410 LRRK2,
anti-phospho-threonine-x-arginine, anti-HA, or anti-GST anti-
bodies. In some cases, an autoradiogram was generated by
exposure to film at 280uC overnight and band intensities were
quantified by densitometry.
GTP hydrolysis assay
The GTPase activity of LRRK2 was measured using the
Colorimetric GTPase assay kit (high sensitivity) according to the
manufacturer’s instructions (Innova Biosciences) and by PEI-
cellulose Thin layer chromatography (TLC) plate analysis as
previously described [20]. For the colorimetric GTPase assay,
components of the reaction included 5 nM LRRK2 protein
(wildtype, G2019S, R1441C, or T1410A) in a buffer containing
50 mM Tris, pH 7.5, 2.5 mM MgCl2, 0.5 mM GTP, 10 mM
ATP, 0.1 mM DTT, and 0.00005% BSA. As controls, some
reactions contained no protein. Total volume for each reaction
was 200 mL and each reaction was done in triplicate. Each
reaction was incubated at 30uC for 0, 15, 30, or 60 min and was
stopped by the addition of 50 mL Gold mix (Pi ColorLock Gold
and Accelerator). After 2 min room temperature incubation,
20 mL stabilizer was added followed by incubation at room
temperature for 30 min. After 30 min, absorbance was recorded
at 635 nm using a SpectraMax 250 plate reader (Molecular
Devices). For GTP hydrolysis assay using TLC plates, HA-tagged
LRRK2 Phosphorylation Motif
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T1410D (G2019S), D1994N) were incubated at 30uC for 60 min
in a buffer with 50 mM Tris-HCl, pH 8.0, 2.5 mM MgCl2,
0.5 mM GTP, 10 mCi [a-
32P] GTP, 10 mM ATP, 0.1 mM DTT,
and 0.00005% BSA. Reactions were stopped with 0.5 M EDTA
and 1 mL was separated by PEI-cellulose TLC plate using 0.5 M
KH2PO4, pH 3.4 buffer. Plates were dried for 30 min and
radioactive bands detected by autoradiography. Background
activity was measured using extracts from vector only transfected
control cells.
GTP-binding assay
GTP-binding assay was performed as previously described
[20,21]. Briefly, GTP-agarose beads (Sigma) were pre-treated with
1X TBS containing 0.01% BSA for 1 h at 4uC to block non-
specific binding sites. Then, the beads were equilibrated in a
binding buffer containing 25 mM MOPS, pH 7.2, 12.5 mM b-
glycerolphosphate, 25 mM MgCl2, 5 mM EGTA, 2 mM EDTA,
0.002% BSA, and 0.25 mM DTT. Cell lysates containing
transfected HA-tagged LRRK2 (wildtype, G2019S, K1347A, or
T1410A (G2019S)) were incubated with the GTP-agarose for 1 h
at 4uC. Controls were performed with no LRRK2 protein. After
incubation, competition experiments were performed by adding
10 mM GTP for an additional 2 h at 4uC. Beads were washed
with binding buffer three times followed by boiling in LDS sample
buffer with reducing agent (Invitrogen). Samples were separated
on 7% NuPAGE Tris-Acetate gels (Invitrogen) and transferred
onto nitrocellulose membranes (Invitrogen). The nitrocellulose
membranes were probed with anti-HA antibody.
LanthaScreen
TM Kinase Assay
LanthaScreen
TM assays were performed as previously described
[7]. Briefly, LRRK2 protein (wildtype, G2019S, or T1410A
(G2019S)) was diluted 1:2 for 15 points starting at 0.15 mg/ml.
Assay reagents were made up to a final of 100 nM fluorescein-
LRRKtide and 50 mM ATP in 1X assay buffer 50 mM HEPES
pH 7.5, 3 mM MgCl2, 0.01% Brij, and 2 mM DTT. The
reactions proceeded for 1 hr at room temperature in the dark.
Reactions were stopped by adding 10 ml of 3 mM EDTA and
1 nM terbium-labeled anti-p-LRRKtide antibody (final concen-
trations) in 1X TR-FRET dilution buffer (20 mM Tris, pH 7.5,
0.02% sodium azide, and 0.01% NP-40 alternative). Plates were
incubated for 1 hr at room temperature in the dark. Finally, plates
were read on Envision plate reader (Perkin Elmer) and emission
ratios at 525 nm and 495 nm were determined.
In-gel digestion and peptide identifications by LC-MS/MS
Recombinant LRRK2 G2019S protein was subjected to an in
vitro autophosphorylation assay as described above for 1 hour. The
reaction was separated on a 3–8% NuPAGE Tris-Acetate gel
(Invitrogen) followed by Coomassie blue staining. The LRRK2
G2019S band was excised and subjected to robotic in-gel digestion
by trypsin as previously described [22]. The peptide samples were
loaded onto a reversed-phase C18 capillary column (5 mm, 200 A ˚,
75 mm610 cm) and coupled to an LTQ-Orbitrap XL mass
spectrometer (ThermoFisher Scientific, San Jose, CA). Peptides
were separated at a flow rate of 0.2 mL/min using a 90 min linear
gradient ranging from 2% to 40% B (mobile phase A: 0.1% formic
acid/2% CH3CN; mobile phase B: 90% CH3CN/0.1% formic
acid). Electrospray voltage was 1.8 kV. For the analysis of
unlabeled peptides, the instrument method consisted of a full
MS scan (scan range 375–1550 m/z, with 30K FWHM resolution
@ m/z=400, target value 2610
6, maximum ion injection time of
500 ms) followed by data-dependent CID scans of the six most
intense precursor ions. Peptide precursor ions were selected with
an isolation window of 2.5 Da, and a target value of 1610
5.
Dynamic exclusion was implemented with a repeat count of 2 and
exclusion duration of 75 sec. The normalized collision energy was
set to 35%.
The MS/MS spectra were searched against human LRRK2
sequence using Bioworks 3.3.1 SP1 with SEQUEST search
algorithm (ThermoFisher Scientific, Version 28). For SEQUEST
searches, the mass windows for precursor and fragment ions were
30 ppm and 1 Da respectively. The search database was the
International Protein Index (IPI), Human division, version 3.56,
concatenated with a reversed version of the same database, to
estimate the false discovery rate. Search space was limited to fully
tryptic peptides with up to 2 missed cleavages. The fixed
modification carbamidomethyl (C) +57.02146 Da was applied.
Four differential modifications were allowed: Phosphophorylation
(STY) +79.9663 Da, Oxidation (MW) +15.9949 Da, and double
Oxidation (W) +31.9898. A total of 2 differential modifications of
any one type, and 3 total modifications were allowed for any single
peptide. The top-ranked peptide-spectrum match (PSM) from
each query spectrum was retained for further analysis. Identified
peptides were mapped to their cognate proteins in the source
database. Phospho-peptides that mapped to LRRK2 were ordered
by the SEQUEST XCorr score, and in cases where the same
phospho-peptide was identified multiple times, the top-scoring
PSM was retained.
Sequence logo analysis
The position-specific scoring matrix (PSSM) logo was generated
by R scripts. Some R code was adapted from the Bioconductor
seqLogo package for DNA alignments [23]. Sequence logos are a
graphical representation of sequence alignments first developed by
Schneider and Stephens [24].
Native PAGE protein analysis
Protein expression analysis by native PAGE was performed as
previously described [25]. Transfected cells were gently harvested
by a cell scraper, divided in half, and pelleted by centrifugation at
2006g for 5 min at 4uC. Cell pellets were resuspended with either
native lysis buffer (phosphate-buffered saline (PBS), pH 7.4, 1x
protease and phosphatase inhibitors (Roche Applied Science),
lysed by four cycles of freezing and thawing, and analyzed on a 3–
12% bis-tris Blue native polyacrylamide gel (Invitrogen) or lysates
combined with SDS-lysis buffer (PBS, pH 7.4, 1% SDS,
1xprotease and phosphatase inhibitors (Roche Applied Science)
and sonicated with 10% power for 10 s on a Branson
dismembranator and analyzed on a 7% Tris acetate SDS gel
(Invitrogen). Prior to PAGE, lysates were centrifuged for 10 min at
20,0006g, and protein content in supernatant was determined by
a BCA assay (Pierce). Proteins resolved in acrylamide were
transferred to PVDF membranes (Immobilon P, Millipore) at 4uC
overnight to ensure complete transfer of high molecular weight
species. In most experiments, PVDF membranes were blocked
with 5% nonfat milk in TBS-T (Tris-buffered saline Tween-20) for
1 h and incubated overnight in blocking buffer supplemented with
anti- HA antibody (Sigma) and developed using electrochemical
luminescence substrate (Pierce).
Results
Identification of a consensus LRRK2 G2019S
phosphorylation site
Kinase specificity is often achieved by recognition of amino
acids surrounding the site of phosphorylation, therefore we
LRRK2 Phosphorylation Motif
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optimal activity. Biotinylated oriented degenerate peptide libraries
synthesized as 10 mers with a fixed phosphoacceptor were used
[18,26–28]. First, to determine whether LRRK2 G2019S
preferred a particular phosphoacceptor residue, peptide substrates
were utilized with either Ser, Thr, or Tyr fixed at the central
residue with flanking degenerate sequence (x-x-x-x-x-S/T/Y-x-x-
x-x) [18]. Threonine was the favored phosphoacceptor when
compared to Ser and Tyr (p,0.001) (Figure 1A), although peptides
with Ser as the phosphoacceptor were also phosphorylated
significantly above negative controls (p,0.05).
Next, specificity to surrounding residues was determined using
positional scanning of the biotinylated oriented peptide library
with peptide substrates in which Thr was fixed as the
phosphoacceptor. Screening of peptides with fixed residues at
the +2 position with LRRK2 G2019S revealed preference for
basic amino acids Arg and Lys (Figure 1B). These results are in
line with studies using recombinant HEK-293 purified LRRK2
G2019S protein [29]. To ensure that selection of Arg at the +2
position was not due to a contaminating kinase, we also
investigated kinase dead LRRK2 D1994A [30]. Phosphorylation
of peptides containing Arg +2 was shown to be LRRK2 G2019S
kinase domain dependent with no phosphorylation by LRRK2
D1994A (Figure 2A).
Quantitation of preference across all residues was calculated
using the ‘‘ratio to mean’’ and ‘‘log scores’’ [31] for each peptide
Figure 1. Primary peptide positional screening scan for LRRK2 G2019S. (A) To determine which phosphoacceptor site LRRK2 G2019S
prefers, fixed phosphoacceptor pools or no peptide were incorporated into a kinase assay with recombinant LRRK2 G2019S and
33P[ATP]. Fixed S=Y-
A-X-X-X-X-X-S-X-X-X-X-A-G-K-K(LC-Biotin)-NH2, Fixed T=Y-A-X-X-X-X-X-T-X-X-X-X-A-G-K-K(LC-Biotin)-NH2, and Fixed Y=Y-A-X-X-X-X-X-Y-X-X-X-X-A-G-
K-K(LC-Biotin)-NH2 where X is a degenerate position (adapted from [18]). Threonine was the favored phosphoacceptor when compared to serine and
tyrosine (**p,0.001). Serine was phosphorylated greater than no peptide control (*p,0.05). (B) Results of the peptide positional scan demonstrates
that Arg/Lys +2 is favored. Shown are peptide pools where Z is a fixed residue at +2 ie X-X-X-X-X-S/T-X-Z-X-X. (C) Table listing the log scores for each
peptide pool. Arg and Lys at the +2 position have highest log scores (bold). Log score calculated as log2[(counts)/(mean counts for all peptides at the
same position)] [31]. N/A denotes peptide pools where CPM counts were equal to or less than no peptide control. (D) Sequence logo representation
for peptide positional scan highlights favored (above line) and disfavored residues (below line). Residues in each stack are sorted by log score with
the height of each letter proportional to the absolute value of the residue’s log score (adapted from [31]). Position 0 is the fixed Ser/Thr
phosphoacceptor site. Residue color code: nonpolar=black, aromatic=green, polar uncharged=red, positively charged=blue, negatively
charged=orange.
doi:10.1371/journal.pone.0013672.g001
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score (1.93) indicating that it is a strongly favored residue. Several
fixed Thr peptide pools, at 23, 22 and +3 positions, also
appeared to be favored. As Thr is a phosphoacceptor we tested
peptides that had phosphothreonine at each of the nine fixed
positions and no preference was detected (data not shown). These
data indicated that the increased signal at these Thr residues in the
original screen is through their additional phosphorylation rather
than a relevant selection. Furthermore, the log scores were input as
a matrix in a sequence logo analysis [24,32] to depict the relative
preference for each amino acid (Figure 1D). This first analysis
revealed the optimal LRRK2 G2019S consensus sequence to be
A-R-G-F-K-T-K-R-R-R.
We sought to further refine the motif by fixing Thr as the
phosphoacceptor and Arg at +2 position (x-x-x-x-T-x-R-x-x) in a
new peptide library. Phenylalanine (Phe) at the 22 position
demonstrated the strongest preference (Figure 3A–3C), in line with
results from the first scan (Figure 1). These data extended the motif
to favor Phe at 22 and Arg at +2. The second analysis therefore
refined the optimal LRRK2 G2019S recognition sequence to K-
K-F-K-T-Q-R-R-K. Consideration of secondary preferences at
the +2 and 22 positions was also considered. Tyrosine is an
aromatic residue, like Phe, and showed the second strongest signal
at the 22 position, therefore may also be considered to influence
selection. Similarly Lysine at the +2 position was highly selected in
the original scan (Figure 1C, 1D) indicating this may also be a
relevant contributor to LRRK2 recognition. Therefore a less
stringent consensus motif of F/Y-x-T-x-R/K was also identified
from these studies.
LRRK2 has been shown to efficiently phosphorylate moesin at
Thr 558, and a peptide, LRRKtide, derived from it [33].
Therefore to confirm the major selections from the positional
scanning technique alanine scan substitutions were performed.
The alanine scan demonstrated that substitution of Arg +2 resulted
in the most significant decrease in phosphorylation efficiency
followed by substitution at the Tyr 22 position (Figure 2B).
Therefore the critical nature of the peptides at +2 and 22
positions were confirmed.
Database searches using a motif scanning algorithm [34]
(scansite.mit.edu) identified candidate substrates for LRRK2
G2019S that contain sites that most resemble the sequences
derived from the two peptide scans (Table 1). The ability of
LRRK2 G2019S to phosphorylate peptides derived from four of
these, ATM, MAP2, Praja1, and ULK1, was assessed due to their
potential physiological relevance to the PD phenotype. All of the
peptides were phosphorylated by LRRK2 G2019S with ATM and
Praja1 phosphorylated at levels similar to LRRKtide (Figure 4A).
Moreover, mutations at Phe 22 and Arg +2 of the ATM peptide
showed a reduction in phosphorylation (Figure 4B) suggesting that
these sites are required for selection.
LRRK2 autophosphorylates at consensus
phosphorylation sites
Since LRRK2 autophosphorylation has been identified in
multiple studies [35–37], we investigated whether the identified
consensus motif is also present in LRRK2 itself. The only match
was at Thr1410 and a peptide generated to include this site was
phosphorylated by LRRK2, indicating its relevance (Figure 5A).
Confirmation and functional characterization of T1410 phos-
phorylation was therefore further investigated in LRRK2 proteins.
To investigate if LRRK2 G2019S autophosphorylates at T-x-
R/K sites, we performed in vitro kinase assays with LRRK2
G2019S protein and immunoblotted with an antibody that
recognizes pT-x-R/K, indicating phosphorylation of this motif
(Figure 5B). LRRK2 G2019S that had undergone autopho-
sphorylation in vitro was further analyzed by liquid chromatogra-
phy and tandem mass spectrometry (LC-MS/MS). Multiple
phosphorylated residues including T1410 were detected that
conformed to the [T/S]-x-[R/K] motif (Supplemental Table S1).
Among the [T/S]-x-[R/K] motif sites phosphorylated were
residues in the ROC domain (S1345), the COR domain (S1536,
T1612), and in the kinase domain (S1913). When LRRK2
T1410A protein in the G2019S background was used in an
autophosphorylation assay, the amount of incorporated
33P was
reduced compared to G2019S (*p,0.05), indicating the loss of the
T1410 phosphoacceptor site (Figure 5C, 5D).
To determine if LRRK2 G2019S autophosphorylates at T1410
in cells, a phosphospecific antibody was generated and utilized.
Recombinant LRRK2 T1410A protein was used to confirm that
the antibody was site specific and phosphospecific (Figure 6A).
Figure 2. LRRK2 G2019S prefers Arg at the +2 position in its substrates. (A) LRRK2 G2019S or a kinase dead mutant (LRRK2 D1994A) was
incubated with either no peptide (negative control), fixed Thr phosphoacceptor pool (positive control), or Arg +2 peptide pool.
33P incorporation by
kinase dead mutant is equivalent to no peptide control showing phosphorylation of Arg +2 peptide pool is LRRK2 G2019S kinase dependent.
Reduced activity was detected between LRRK2 D1994A and LRRK2 G2019S (**p,0.001). (B) Alanine scanning of known LRRK2 substrate LRRKtide
(TKPRLGRDKYKTLRQIRQ-biotin) also shows preference for Arg at +2. Alanine was substituted for each residue from 25t o+4. Note reduction of
phosphorylation upon substitution of Arg +2 compared to wildtype LRRKtide.
doi:10.1371/journal.pone.0013672.g002
LRRK2 Phosphorylation Motif
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LRRK2 and LRRK2 G2019S autophosphorylate, with a kinase
dead version (D1994N) not autophosphorylating at this site
(Figure 6B). Together these data demonstrate that LRRK2
autophosphorylates at T1410 in vitro and in cells confirming and
extending on data obtained previously using mass spectrometry
[35–37].
Mutation of T1410 affects GTPase activity but not GTP
binding, autophosphorylation, or kinase activity
Next we studied the consequences of mutating LRRK2 at
T1410 on its functional properties. To assay whether T1410
influences kinase activity we performed assays with LRRKtide as
the substrate (Figure 7A). As expected, LRRK2 G2019S was more
active than wild-type LRRK2, but no significant difference in
kinase activity was detected between LRRK2 G2019S and
T1410A (G2019S) with LRRKtide. These data are consistent
with the notion that LRRK2 T1410A does not affect kinase
activity on an exogenous substrate [35].
Dimerization has been postulated to be necessary for LRRK2
kinase activity and the GTPase domain important in mediating
dimerization [25,38–40]. Therefore we investigated the effect of
mutation of T1410 on dimerization of LRRK2 in HEK293 cells.
Native-PAGE analysis of full length phosphomimetic LRRK2
T1410D compared to wildtype demonstrated slightly increased
dimer formation, whereas T1410A mutation had no effect
(Figure 7B). These data suggest that modification at T1410 may
have a subtle effect on dimerization.
Because T1410 is located within the GTPase domain it led us
to investigate whether it affected the GTP hydrolysis activity of
LRRK2. Therefore, a malachite green based colorimetric assay
was utilized to measure inorganic phosphate released by LRRK2
[41–44]. To assess proper GTP hydrolysis, Ras and Ras(G12V),
a mutant that binds GTP, but is deficient in GTP hydrolysis
were used to validate the assay [45–47]. Wildtype Ras displayed
significantly higher GTPase activity compared to Ras G12V
(data not shown). LRRK2 T1410A (G2019S) demonstrated a
reduction in GTP hydrolysis when compared to LRRK2
wildtype, G2019S, and R1441C, a clinically observed mutation
Figure 3. Secondary peptide positional scan supports selection for Phe at the 22 position. (A) Each peptide pool has threonine fixed as
the phosphoacceptor and Arg fixed at the +2 position. Each bar represents one peptide pool. Shown are peptide pools where Z is a fixed residue at
22 ie X-X-X-Z-X-T-X-R-X-X where X is a degenerate position (adapted from [18]). (B) Table lists the log scores for each peptide pool. Phe at the 22
position has the highest log score (bold). (C) Sequence logo representation for secondary peptide scan. Position 0 is Thr and position +2 is Arg.
doi:10.1371/journal.pone.0013672.g003
Table 1. Potential LRRK2 substrates.
Protein Site Sequence Score
Serine-protein kinase ATM (Ataxia telangiectasia mutated) 1769 AYLQPFRTSRKKFLE 0.13
Microtubule-associated protein 2 (MAP 2) 1433 RKEKPFKTGRGRIST 0.14
ADAM 29 precursor (A disintegrin and metalloproteinase domain 29) 161 SEEKQFSTMRSGFMQ 0.15
Fanconi anemia group C protein (FACC protein) 171 NHLNGFNTQRRMAPE 0.16
Pancreatic lipase 83 ISGSNFKTNRKTRFI 0.17
Cartilage leucine-rich protein 350 FRSCKFPTKRSKKAG 0.18
Homeobox protein Nkx-3.2 261 FQNRRYKTKRRQMAA 0.18
Homeobox protein Nkx-3.1 179 FQNRRYKTKRKQLSS 0.19
Chromodomain-helicase-DNA-binding protein 2 197 RVKKQPKTQRGKRKK 0.19
Serine/threonine-protein kinase WNK4 1196 LSKGSFPTSRRNSLQ 0.20
Protein C21orf5 2256 TLNGAFKTQRQLPAD 0.22
Lactase-phlorizin hydrolase 1914 KRSKQGKTQRSQQEL 0.23
Splicing factor arginine/serine-rich 11 (p54) 332 TPPKSYSTARRSRSA 0.23
Ubiquitin protein ligase Praja1 74 RSRSPFSTTRRSWDD 0.23
5-oxoprolinase 622 DMLRAFGTSRQARGL 0.24
Syntabulin 560 TVLWAFSTQRGGTDP 0.24
Serine/threonine-protein kinase ULK1 456 QSPTQFQTPRSSAIR 0.24
Cylicin II 45 PKPQRPGTKRRSKPS 0.24
Microtubule plus end-directed kinesin motor 3A 684 KGKARPKTGRRKRSA 0.24
Ras-related protein Rab-21 200 NGSSQPGTARRGVQI 0.25
Transforming growth factor beta 1 precursor (TGF-beta 1) 241 VDINGFTTGRRGDLA 0.25
Dual specificity phosphatase Cdc25A 288 EESPPGSTKRRKSMS 0.25
INT-2 proto-oncogene protein precursor (Fibroblast growth factor-3) 169 RPRRGFKTRRTQKSS 0.25
Inhibitor of growth protein 1 326 PKEKKAKTSKKKKRS 0.25
Serine/threonine-protein kinase Nek3 288 IKNSKHNTPRKKTNP 0.25
The top-scoring predicted hits that match the LRRK2 phosphorylation consensus were identified using Scansite (scansite.mit.edu).
doi:10.1371/journal.pone.0013672.t001
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PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13672Figure 4. LRRK2 G2019S phosphorylates predicted peptide substrates. (A) Sequences for ATM, MAP2, Praja1, and ULK1 were synthesized as
listed in Table 1. All peptides were biotinylated and incorporated into kinase assays with 5 nM LRRK2 G2019S. (B) Various mutations of biotinylated
ATM peptide: AYLQPFRTSRKKFLE were incorporated into kinase assays with LRRK2 G2019S to demonstrate that Phe 22 and Arg +2 confer selection
of the ATM peptide.
doi:10.1371/journal.pone.0013672.g004
Figure 5. LRRK2 autophosphorylates at T-x-R/K in vitro. (A) Kinase assays were performed with LRRKtide and LRRK2 T1410 peptide with LRRK2
G2019S (**p,0.001 in comparison with no peptide). The LRRK2 T1410 peptide sequence was STHPHFMTQRALYLA (B) Autophosphorylation assay
using recombinant LRRK2 G2019S with and without ATP confirms that autophosphorylation occurs at T-x-R/K sites. Reaction products were resolved
by SDS-PAGE and immunoblotted with anti-pT-x-R/K antibody. (C) Recombinant LRRK2 protein wildtype, G2019S, and T1410A (G2019S) were assayed
for autophosphorylation activity. Activities detected by
33P autoradiogram (top panel). Equal protein loading shown by anti-GST western blot
(bottom panel). (D) Experiments performed in triplicate, quantified, and normalized (*p,0.05 compared to G2019S).
doi:10.1371/journal.pone.0013672.g005
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PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13672in the GTPase domain of LRRK2 (Figure 7C). Consistent with
previous reports, R1441C showed decreased GTPase activity
compared to both wildtype and G2019S [20,21,39,48]. Further-
more, full length LRRK2 was immunoprecipitated from cells
and assessed for GTP hydrolysis using thin-layer chromatogra-
phy analysis. LRRK2 T1410A demonstrated a reduction in
GTPase activity compared to LRRK2 wildtype, G2019S, and
T1410D (Figure 7D). Interestingly, the kinase dead mutant,
Figure 6. Characterization of LRRK2 autophosphorylation at T1410. (A) Using LRRK2 G2019S and LRRK2 T1410A (G2019S) recombinant
proteins in autophosphorylation assays, LRRK2 pT1410 antibody was shown to be site specific (lane 5 versus lane 6) and phospho-specific (lanes 2
and 8 versus lane 5). Phosphorylated LRRK2 G2019S is detected with the LRRK2 pT1410 antibody but not with pre-immune serum. (B) Full length
LRRK2 constructs (as indicated) were transfected into HEK-293FT cells, lysed on the plate, and immunoprecipitated with anti-HA affinity gel. Reaction
products were analyzed by SDS-PAGE followed by western analysis with pT1410 and HA antibodies. Autophosphorylation was detected at T1410 in
wildtype and G2019S but not in kinase dead LRRK2 D1994N or LRRK2 T1410A (G2019S). Equivalent LRRK2 protein levels were confirmed by anti-HA
immunoreactivity.
doi:10.1371/journal.pone.0013672.g006
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PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13672D1994N, also displayed reduced GTPase activity, that may be
indicative of its inability to autophosphorylate. LRRK2 K1347A,
which does not bind GTP [30], displayed activity similar to
vector control background.
To further investigate the GTPase activity of T1410A, GTP
binding assays using immobilized GTP were performed using
transfected cell lysates containing LRRK2 wildtype, G2019S,
K1347A, and T1410A(G2019S). LRRK2 T1410A (G2019S),
wildtype, and G2019S all bound strongly to GTP (Figure 7E).
K1347A, a mutation in the GTPase domain [30], inhibited
GTP binding (Figure 7E). Moreover, addition of molar excess
GTP competed for protein binding and eliminated pull-down of
L R R K 2s u g g e s t i n gt h a tt h eG T Pase domain was bound to the
GTP beads. GTP binding assays using GST-tagged LRRK2
wildtype, G2019S, R1441C, and T1410A recombinant protein
displayed similar results suggesting that mutations do not affect
GTP binding (data not shown). These results are consistent
with previous findings that R1441C does not increase GTP
binding even though GTPase activity was decreased [20,21].
Together these data suggest that LRRK2 T1410A results in
decreased GTP hydrolysis activity without a reduction in
binding to GTP.
Discussion
Our studies identified the motif F/Y-x-T-x-R/K to be the
core sequence that LRRK2 prefers to phosphorylate, this was
also reported in the consensus peptide substrate Nictide
(RLGWWRFYTLRRARQGNTKQR) [29]. Our sequence pref-
erence differs from that of Nictide (WRFYTLRRA) with finding
KKFKTQRRK as optimal. These differences suggest that there is
low strength of selection of sites outside of the -2 and +2 positions.
This is important in assessing the potential substrates of LRRK2
where less precedence should be given to these weaker positions.
Interestingly we confirm that LRRK2 is a Thr preferring kinase,
although rare, this preference for Thr over Ser has been reported
for LRRK2 and other additional kinases [29,49,50].
Database searches using the consensus phosphorylation se-
quence revealed a number of potential downstream targets that
may function in LRRK2 signaling. Of these, ATM, ULK1,
Praja1, and MAP2 are neuronal and have potential relevance to
PD. Moreover, peptidic sequences from them containing the
identified LRRK2 consensus motif were phosphorylated. Muta-
tions in ATM and LRRK2 can cause neurodegeneration
and induce cell death respectively [51–53]. Moreover, insulin
Figure 7. Functional characterization of modulation of LRRK2 at T1410. (A) A LanthaScreen assay was used to assess LRRK2 T1410A kinase
activity. Titration of wildtype, G2019S, and T1410A (G2019S) LRRK2 proteins demonstrate that mutation T1410A does not affect phosphorylation of
LRRKtide. (B) To investigate dimer formation HEK-293T cells were transfected with the indicated LRRK2 constructs. Cell pellets were split equally for
lysis by freeze/thaw cycles directly in PBS or lysis with 1% SDS and PBS with sonication, and 10 ug of protein lysate was loaded onto a native gel (3–
12% Bis-Tris) or an SDS gel (7% Tris acetate-SDS), respectively. LRRK2 complexes were visualized with the anti-HA antibody by Western blot with
standard ECL. Dimer-sized structures are evident (signal from 480 to 550 kDa), monomeric LRRK2 (278 kDa) is only visible by overexposure
(Supplemental Figure S1, [25]).Western blots representative of five independent experiments are shown. Normalization of the LRRK2 dimer to total
LRRK2 protein (SDS-solubilized) was done using densitometry analysis. **p,0.001, *p,0.05 n.s., nonsignificant in comparison with wild-type LRRK2,
assessed by unpaired Student-Newman-Keuls Multiple Comparison Test. (C) Investigation of LRRK2 GTPase activity shows that LRRK2 T1410A has
reduced GTPase activity compared to wildtype. A colorimetric assay was used to assess GTPase activity for LRRK2 wildtype, G2019S, R1441C, and
T1410A. The assay was performed in triplicate. Reduced activity was seen between T1410A and wildtype at time points 15, 30, and 60 minutes
(p,0.01). (D) Full length HA-tagged LRRK2 proteins were immunoprecipitated and assayed for GTP hydrolysis using thin-layer chromatography.
Reduced activity was seen between LRRK2 T1410A and wildtype (*p,0.05). (E) GTP binding was not affected by T1410 mutation. Full length LRRK2
proteins were precipitated from cell lysates using GTP-agarose beads. In some cases, 10 mM GTP was added for competition. LRRK2 K1347A was
included as a negative control since this mutant does not bind GTP. Reaction products were resolved by SDS-PAGE and immunoblotted with anti-HA
antibody (upper panel). LRRK2 expression was equivalent across all transfections as indicated by immunoblotting whole cell lysates with anti-HA
antibodies (lower panel).
doi:10.1371/journal.pone.0013672.g007
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PLoS ONE | www.plosone.org 10 October 2010 | Volume 5 | Issue 10 | e13672treatment has been shown to induce phosphorylation of 4E-BP1 in
an ATM-dependent manner [54] and LRRK2 has been shown to
phosphorylate 4E-BP1 [16,55], indicating potential interplay
between these pathways. ULK1 as a potential substrate suggests
a mechanism by which LRRK2 could regulate autophagy. ULK1
plays a critical role during the activation of autophagy (reviewed in
[56]) and knockdown of ULK1 suggests its involvement in
starvation-dependent autophagy [57]. Knockdown of LRRK2
induces autophagic activity [58], and autophagy has been linked to
LRRK2 mediated neurite retraction [59]. Moreover, ULK1 is
phosphorylated although the kinase responsible remains unknown
[60,61]. MAP2 belongs to the microtubule-associated protein
family and is found in neurons where it binds and stabilizes
microtubules (reviewed in [62]). In addition, MAP2 interacts with
actin filaments promoting neurite initiation [62,63] and MAP2
phosphorylation alters binding to microtubules, the main mech-
anism of microtubule dynamic regulation (reviewed in [64]). Since
LRRK2 affects neurite growth and actin cytoskeleton rearrange-
ment [52,59,65], MAP2 as a potential substrate could explain such
effects. Praja1 is an ubiquitin E3 ligase that is highly expressed in
the brain [66,67]. Praja1 has been shown to ubiquitinate Dlxin-1,
a Dlx/Msx-binding protein that binds to the homeoprotein Dlx5
regulating its transcriptional activity [68]. Since the ubiquitin/
proteasome pathway is associated with neurodegeneration [69]
and E3 ligases are regulated by phosphorylation [70], LRRK2
may regulate Praja1, warranting further investigation of this as a
potential substrate.
The identified consensus site intriguingly correlated with the
sequence surrounding T1410 of LRRK2 itself. LRRK2 autopho-
sphorylation has been thoroughly investigated and recently, three
groups reported on LRRK2 autophosphorylation sites that
overlap with this study [35–37]. The relevance of autopho-
sphorylation on the ultimate function of LRRK2 remains unclear.
The phosphomimetic T1491D appears to modulate kinase
activity, although phosphorylation at other sites appears to have
limited effects on LRRK2’s ability to phosphorylate substrates
[35]. Our findings also suggest that T1410 does not significantly
alter LRRK2’s kinase activity. Functionality of LRRK2 as a kinase
has been demonstrated to require its dimerization [25]. Since
T1410 lies in the Roc domain which has been shown to be
involved in dimerization [39], it is conceivable that phosphoryla-
tion could modulate dimerization. Our studies indicate only a
minor effect on dimerization is seen with the T1410D phospho-
mimetic mutant. Together the lack of significant effect of T1410
mutation on dimerization and kinase activity indicate that it does
not have a major functional consequence on LRRK2’s phosphor-
ylating activity towards other substrates.
GTPase activity of LRRK2 is another key property that may
have functional consequences. Although some studies have
implicated GTPase activity in controlling kinase activity
[21,30,38,48,71,72], in yeast activity of the GTPase domain alone
has been shown to influence toxicity [73]. Our studies indicated
that mutation of T1410 can influence GTP hydrolysis, but with no
gross effect on GTP binding, although we cannot discount more
subtle effects on its binding properties [74]. The magnitude of
these changes was small, but in line with changes observed in the
pathogenic mutant R1441C in our studies and other reports [73].
It will be interesting to further confirm these results with directly
phosphorylated T1410, as our studies have used a mutagenic
approach that does not always fully recapitulate the physiological
role of phosphorylation [75].
Identification of the LRRK2 G2019S phosphorylation motif
has given insight to LRRK2’s potential substrates and consequent
pathophysiological function. These studies indicate that autopho-
sphorylation may play a key role in regulating GTPase activity for
functional consequence. Additionally, phosphorylation of other
substrates identified in these studies suggest potential roles in
disease. Uncovering the pathophysiological interaction network of
LRRK2 is critical to understanding its contribution to PD
pathogenesis.
Supporting Information
Table S1 All phosphopeptides identified from LRRK2 G2019S.
Recombinant LRRK2 G2019S was assayed for autophosphoryla-
tion followed by analysis by LC-MS/MS. This table lists each
phosphopeptide identified from LRRK2 G2019S. Phosphopep-
tides identified from LRRK2 G2019S that are phosphorylated at
[T/S]-x-[R/K[where x is any amino acid are bold. Peptide
sequence, delta mass, charge, XCorr, site, and number of peptide
to spectrum matches are listed. Phosphorylation is denoted by
caret (‘), asterisk (*) denotes oxidation, and pound (#) denotes
carbamidomethylation.
Found at: doi:10.1371/journal.pone.0013672.s001 (0.12 MB
DOC)
Figure S1 Overexposed Native-Blue PAGE. Overexposed
Native-Blue PAGE shows the migration of high molecular weight,
dimeric, and monomeric LRRK2. HEK-293T cells were
transfected with empty vector or LRRK2 wildtype construct. Cell
pellets were lysed by freeze/thaw cycles directly in PBS and 10 ug
of protein lysate was loaded onto a native gel (3–12% Bis-Tris).
LRRK2 complexes were immunoblotted with anti-HA antibody.
Found at: doi:10.1371/journal.pone.0013672.s002 (0.29 MB TIF)
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